Verici Dx plc (LON:VRCI – Get Free Report) shares traded down 15.8% on Thursday . The company traded as low as GBX 0.40 and last traded at GBX 0.40. 133,709 shares were traded during trading, a decline of 92% from the average session volume of 1,654,991 shares. The stock had previously closed at GBX 0.48.
Verici Dx Price Performance
The stock has a market capitalization of £6.05 million, a price-to-earnings ratio of -0.14 and a beta of 1.40. The company has a fifty day simple moving average of GBX 0.50 and a 200 day simple moving average of GBX 0.65. The company has a debt-to-equity ratio of 11.36, a quick ratio of 8.49 and a current ratio of 0.91.
About Verici Dx
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
Featured Articles
- Five stocks we like better than Verici Dx
- Oklo Stock Could Be Ready for Another Massive Run
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
